Overview
Sign in Register Sign out My acount Search Headlines Bio Developments Upstream Procesing Downstream Procesing Markets & Regulations Biopharma Culture Promotional Features Site ArchiveMultimedia Hot Topics Biosimilars COVID-19 Pipelines Antibody-Drug Conjugates Emerging Markets Cel & Gene Therapies Site ArchiveMultimediaResources Type of resourcesEvents Al Events Online Events Editorial Webinars Shows & Conferences Events Related Site By Rachel Arthur contact 20-Oct-202 - Last updated on 20-Oct-202 at 09:07 GMT Related tags: Dementia, Alzheimer's disease, Aducanumab, Alzheimer, Clinical trials, WHO, Patient centricity, Patient recruitment function sanitize_gpt_value2(gptValue) { var vOut = "; var aTags = gptValue.split(','); var reg = new RegExp('\W+', "g"); for (var i=0; i < aTags.length; i+) { vOut += aTags[i].trim().replace(reg, '-').substring(0,40); if (i!=(aTags.length-1) vOut +=', ' } vOut = vOut.toLowerCase(); return vOut; } $(document).ready(function() { dataLayerNews = {}; dataLayerNews.related_tags = sanitize_gpt_value2("Dementia, Alzheimer's disease, Aducanumab, Alzheimer, Clinical trials, WHO, Patient centricity, Patient recruitment"); dataLayer.push(dataLayerNews); }); Dementia is set to reach 78 milion people by the end of the decade.
Details
It is already the seventh leading cause of death globaly; and yet research in the area acounts for les than 1.5% of total health research output.In publishing its blueprint for dementia research, the WHO sets out the chalenges in drug development and clinical trials: giving policy makers, funders, pharmaceutical companies and academics guidance on how dementia research can become more eficient, equitable and impactful.“During the COVID-19 pandemic, we have learned how fast we can advance research and development if we act in a cordinated maner," says Dr Soumya Swaminathan Chief Scientist World Health Organi